Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/18497
Ficheiros no ítem
Metadatos do ítem
Título: | Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus |
Autor/a: | Marín López, Alejandro Calvo Pinilla, Eva Barriales, Diego Lorenzo, Gema Benavente Martínez, Francisco Javier Brun, Alejandro Martínez Costas, José Manuel Ortego, Javier |
Centro/Departamento: | Universidade de Santiago de Compostela. Centro de Investigación en Química Biolóxica e Materiais Moleculares Universidade de Santiago de Compostela. Departamento de Bioquímica e Bioloxía Molecular |
Palabras chave: | Bluetongue | Microspheres | MVA | Multiserotype | Vaccine | |
Data: | 2017-06 |
Editor: | Elsevier |
Cita bibliográfica: | Marín-López, A., Calvo-Pinilla, E., Barriales, D., Lorenzo, G., Benavente, J., & Brun, A. et al. (2017). Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(−/−) mice conferring protection against serotypes 1 and 4 of bluetongue virus. Antiviral Research, 142, 55-62. doi: 10.1016/j.antiviral.2017.03.010 |
Resumo: | Bluetongue virus (BTV) is the causative agent of bluetongue disease (BT), which affects domestic and wild ruminants. At the present, 27 different serotypes have been documented. Vaccination has been demonstrated as one of the most effective methods to avoid viral dissemination. To overcome the drawbacks associated with the use of inactivated and attenuated vaccines we engineered a new recombinant BTV vaccine candidate based on proteins VP2, VP7, and NS1 of BTV-4 that were incorporated into avian reovirus muNS-Mi microspheres (MS-VP2/VP7/NS1) and recombinant modified vaccinia virus Ankara (rMVA). The combination of these two antigen delivery systems in a heterologous prime-boost vaccination strategy generated significant levels of neutralizing antibodies in IFNAR(−/−) mice. Furthermore, this immunization strategy increased the ratio of IgG2a/IgG1 in sera, indicating an induction of a Th1 response, and elicited a CD8 T cell response. Immunized mice were protected against lethal challenges with the homologous serotype 4 and the heterologous serotype 1 of BTV. All these results support the strategy based on microspheres in combination with rMVAs as a promising multiserotype vaccine candidate against BTV |
Versión do editor: | https://doi.org/10.1016/j.antiviral.2017.03.010 |
URI: | http://hdl.handle.net/10347/18497 |
DOI: | 10.1016/j.antiviral.2017.03.010 |
ISSN: | 0166-3542 |
Dereitos: | © 2017 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
Coleccións
-
- BBM-Artigos [91]
- CIQUS-Artigos [474]
O ítem ten asociados os seguintes ficheiros de licenza: